CD4 and HIV infectious disease: MHC-class-II-deficient patients seem to sufficiently control EBV [29], but compromising IL-2 production, primarily by CD4+ T cells, with the immune suppressant tacrolimus (FK506) or the depletion of CD4+ T cells due to HIV infection increases EBV-associated pathologies [15,30,31,32].